| Malignant Uterine Neoplasm altered in cohorts of …ALTERED_INderived200 of 626show all (up to 200) |
|---|
| ← altered in cohorts of | ADRM1 45 / 57 cases (79 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GATA5 45 / 57 cases (79 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMA7 45 / 57 cases (79 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AHSG 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARFGEF2 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A3 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CABLES2 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COL20A1 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FNDC11 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GP5 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HRH3 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KNG1 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LSM14B 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTG2 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OSBPL2 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RBBP8NL 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPS21 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SS18L1 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STAU1 44 / 57 cases (77 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV5 43 / 57 cases (75 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNQ2 43 / 57 cases (75 %) · ssm · TCGA-UCS | — | — | Uterine Carcinosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNIK 228 / 306 cases (75 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | BCHE 226 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN16 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | FNDC3B 226 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC7A14 226 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPATA16 226 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TBL1XR1 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBBX 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCC5 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTRT3 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A5 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | BCL6 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN11 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LPP 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC31 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC34 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYNN 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | P3H2 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PEX5L 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLD1 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRKCI 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SEC62 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SKIL 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | TP63 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | WDR49 225 / 306 cases (74 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCF3 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTL6A 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A4 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | ECT2 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GHSR 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL1RAP 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | IQCG 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRIQ4 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MB21D2 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | MCF2L2 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MECOM 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NCEH1 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OPA1 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PHC3 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD2 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SAMD7 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC2A2 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLITRK3 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM207 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFSF10 224 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS8 224 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | AP2M1 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC39 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRD 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DGKG 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF2B5 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF5A2 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FGF12 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | GOLIM4 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR160 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HRG 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNMB2 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LIPH 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | MFN1 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPL47 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGZ 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PLAAT1 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL22L1 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RUBCN 223 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINI2 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SOX2 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZMAT3 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF639 223 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADIPOQ 222 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC50 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | DLG1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | EEF1AKMT4-ECE2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | EHHADH 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF4G1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | GMNC 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3C 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3D 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3E 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHL24 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHL6 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | LRCH3 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LSG1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MCCC1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | MELTF 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | NAALADL2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PYDC2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINI1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM212 222 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM44 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | TPRG1 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | UBXN7 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | USP13 222 / 306 cases (73 %) · ssm · TCGA-CESC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | YEATS2 222 / 306 cases (73 %) · ssm · TCGA-CESC · largest of 3 cohorts | — | — | Cervical Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | TTN 297 / 559 cases (53 %) · ssm · TCGA-UCEC · largest of 9 cohorts | — | — | Endometrial Carcinoma | 9 | Observed | gdc | graph → |
| ← altered in cohorts of | OBSCN 296 / 559 cases (53 %) · ssm · TCGA-UCEC · largest of 8 cohorts | — | — | Endometrial Carcinoma | 8 | Observed | gdc | graph → |
| ← altered in cohorts of | RYR2 291 / 559 cases (52 %) · ssm · TCGA-UCEC · largest of 9 cohorts | — | — | Endometrial Carcinoma | 9 | Observed | gdc | graph → |
| ← altered in cohorts of | ASH1L 289 / 559 cases (52 %) · ssm · TCGA-UCEC · largest of 6 cohorts | — | — | Endometrial Carcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | USH2A 286 / 559 cases (51 %) · ssm · TCGA-UCEC · largest of 8 cohorts | — | — | Endometrial Carcinoma | 8 | Observed | gdc | graph → |
| ← altered in cohorts of | FLG 283 / 559 cases (51 %) · ssm · TCGA-UCEC · largest of 9 cohorts | — | — | Endometrial Carcinoma | 9 | Observed | gdc | graph → |
| ← altered in cohorts of | CACNA1E 281 / 559 cases (50 %) · ssm · TCGA-UCEC · largest of 6 cohorts | — | — | Endometrial Carcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | PTEN 941 / 1,882 cases (50 %) · ssm · ucec_ancestry_cds_msk_2023 · largest of 14 cohorts | — | — | Endometrial Carcinoma | 14 | Observed | cbioportal | graph → |
| ← altered in cohorts of | HMCN1 278 / 559 cases (50 %) · ssm · TCGA-UCEC · largest of 8 cohorts | — | — | Endometrial Carcinoma | 8 | Observed | gdc | graph → |
| ← altered in cohorts of | CEP350 277 / 559 cases (50 %) · ssm · TCGA-UCEC · largest of 3 cohorts | — | — | Endometrial Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | CSMD3 277 / 559 cases (50 %) · ssm · TCGA-UCEC · largest of 8 cohorts | — | — | Endometrial Carcinoma | 8 | Observed | gdc | graph → |
| ← altered in cohorts of | HRNR 277 / 559 cases (50 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASPM 275 / 559 cases (49 %) · ssm · TCGA-UCEC · largest of 6 cohorts | — | — | Endometrial Carcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | GON4L 275 / 559 cases (49 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NFASC 271 / 559 cases (48 %) · ssm · TCGA-UCEC · largest of 4 cohorts | — | — | Endometrial Carcinoma | 4 | Observed | gdc | graph → |
| ← altered in cohorts of | CSMD1 270 / 559 cases (48 %) · ssm · TCGA-UCEC · largest of 8 cohorts | — | — | Endometrial Carcinoma | 8 | Observed | gdc | graph → |
| ← altered in cohorts of | INSRR 269 / 559 cases (48 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDE4DIP 269 / 559 cases (48 %) · ssm · TCGA-UCEC · largest of 2 cohorts | — | — | Endometrial Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SPTA1 269 / 559 cases (48 %) · ssm · TCGA-UCEC · largest of 6 cohorts | — | — | Endometrial Carcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | SETDB1 267 / 559 cases (48 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COPA 266 / 559 cases (48 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | F5 266 / 559 cases (48 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC16 266 / 559 cases (48 %) · ssm · TCGA-UCEC · largest of 9 cohorts | — | — | Endometrial Carcinoma | 9 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF2 265 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRRC2C 265 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYST 264 / 559 cases (47 %) · ssm · TCGA-UCEC · largest of 6 cohorts | — | — | Endometrial Carcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | NES 264 / 559 cases (47 %) · ssm · TCGA-UCEC · largest of 2 cohorts | — | — | Endometrial Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NUP210L 264 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF9 263 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KIF26B 263 / 559 cases (47 %) · ssm · TCGA-UCEC · largest of 2 cohorts | — | — | Endometrial Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PIK3C2B 263 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POGZ 263 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CACNA1S 262 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FLG2 262 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP1A2 261 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KIF14 261 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NAV1 261 / 559 cases (47 %) · ssm · TCGA-UCEC · largest of 2 cohorts | — | — | Endometrial Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TG 261 / 559 cases (47 %) · ssm · TCGA-UCEC · largest of 5 cohorts | — | — | Endometrial Carcinoma | 5 | Observed | gdc | graph → |
| ← altered in cohorts of | CEP19 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC20 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCBP2 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NCBP2AS2 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NRROS 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PAK2 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGX 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SENP5 97 / 208 cases (47 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TCHH 260 / 559 cases (47 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF11 259 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARID4B 259 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KIF21B 259 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RUSC1 259 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF687 259 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAMTSL4 258 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASTN1 258 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BDH1 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CR1 258 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CRB1 258 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO45 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | FYTTD1 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OLFML2B 258 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAPPA2 258 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCYT1A 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF168 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC51A 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC9C2 258 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMCO1 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TCTEX1D2 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TFRC 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TM4SF19 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TM4SF19-TCTEX1D2 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TPR 258 / 559 cases (46 %) · ssm · TCGA-UCEC · largest of 3 cohorts | — | — | Endometrial Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | WDR53 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ZDHHC19 96 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC · largest of 2 cohorts | — | — | Cervical Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | BCL9 257 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMSAP2 257 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPRD2 257 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEMA4A 257 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADCY10 256 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP30 256 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CENPF 256 / 559 cases (46 %) · ssm · TCGA-UCEC · largest of 2 cohorts | — | — | Endometrial Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HEATR1 256 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDC4 256 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB41 256 / 559 cases (46 %) · ssm · TCGA-UCEC | — | — | Endometrial Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LMLN 95 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL35A 95 / 208 cases (46 %) · ssm · CGCI-HTMCP-CC | — | — | Cervical Carcinoma | 1 | Observed | gdc | graph → |